Drug Profile
Research programme: anti-HER3 monoclonal antibody - AstraZeneca
Alternative Names: MEDI-3379Latest Information Update: 09 Aug 2021
Price :
$50
*
At a glance
- Originator MedImmune
- Developer AstraZeneca
- Class Monoclonal antibodies
- Mechanism of Action ERBB-3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Breast-cancer in USA (Parenteral)
- 20 Oct 2013 Preclinical trials in Breast cancer in USA (Parenteral)